연구성과로 돌아가기

2021 연구자 정보 (37 / 1146)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 교신저자 여부 Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Nellist, Peter D.
(Nellist, PD)
Univ Oxford, Dept Mat, Oxford OX1 3PH, England

[JCR상위 2.1] Significant Performance Improvement in n-Channel Organic Field-Effect Transistors with C60:C70 Co-Crystals Induced by Poly(2-ethyl-2-oxazoline) Nanodots SCIE 2.1 CHEMISTRY, MULTIDISCIPLINARY;CHEMISTRY, PHYSICAL;MATERIALS SCIENCE, MULTIDISCIPLINARY;NANOSCIENCE & NANOTECHNOLOGY;PHYSICS, APPLIED;PHYSICS, CONDENSED MATTER ykimm@knu.ac.kr;thomas.anthopoulos@kaust.edu.sa;donal.bradley@physics.ox.ac.uk;
Noh, Siwoo
(Noh, S)
POSTEC, Pohang Accelerator Lab, Pohang 37673, Gyeongsangbuk D, South Korea

[JCR상위 2.1] Crystal Phase Transition Creates a Highly Active and Stable RuCX Nanosurface for Hydrogen Evolution Reaction in Alkaline Media SCIE 2.1 CHEMISTRY, MULTIDISCIPLINARY;CHEMISTRY, PHYSICAL;MATERIALS SCIENCE, MULTIDISCIPLINARY;NANOSCIENCE & NANOTECHNOLOGY;PHYSICS, APPLIED;PHYSICS, CONDENSED MATTER hklim@kangwon.ac.kr;ysyoun@yu.ac.kr;sichoi@knu.ac.kr;
Varambhia, Aakash
(Varambhia, A)
Univ Oxford, Dept Mat, Oxford OX1 3PH, England

[JCR상위 2.1] Significant Performance Improvement in n-Channel Organic Field-Effect Transistors with C60:C70 Co-Crystals Induced by Poly(2-ethyl-2-oxazoline) Nanodots SCIE 2.1 CHEMISTRY, MULTIDISCIPLINARY;CHEMISTRY, PHYSICAL;MATERIALS SCIENCE, MULTIDISCIPLINARY;NANOSCIENCE & NANOTECHNOLOGY;PHYSICS, APPLIED;PHYSICS, CONDENSED MATTER ykimm@knu.ac.kr;thomas.anthopoulos@kaust.edu.sa;donal.bradley@physics.ox.ac.uk;
Yoon, Sun Geun
(Yoon, SG)
Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Program Nano Sci & Technol, Seoul 08826, South Korea
0000-0002-6222-8962
Yoon, Sun Geun
[JCR상위 2.1] Electron Density-Change in Semiconductor by Ion-Adsorption at Solid-Liquid Interface SCIE 2.1 CHEMISTRY, MULTIDISCIPLINARY;CHEMISTRY, PHYSICAL;MATERIALS SCIENCE, MULTIDISCIPLINARY;NANOSCIENCE & NANOTECHNOLOGY;PHYSICS, APPLIED;PHYSICS, CONDENSED MATTER younskim@snu.ac.kr;
Youn, Young-Sang
(Youn, YS)
교신저자 Yeungnam Univ, Dept Chem, Gyongsan 38541, Gyeongsangbuk D, South Korea
0000-0003-4201-3152
Youn, Young-Sang
[JCR상위 2.1] Crystal Phase Transition Creates a Highly Active and Stable RuCX Nanosurface for Hydrogen Evolution Reaction in Alkaline Media SCIE 2.1 CHEMISTRY, MULTIDISCIPLINARY;CHEMISTRY, PHYSICAL;MATERIALS SCIENCE, MULTIDISCIPLINARY;NANOSCIENCE & NANOTECHNOLOGY;PHYSICS, APPLIED;PHYSICS, CONDENSED MATTER hklim@kangwon.ac.kr;ysyoun@yu.ac.kr;sichoi@knu.ac.kr;
Anthony Dacosta, Noshir
(Dacosta, NA)


[JCR상위 2.2] Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor plus (HR+), HER2-metastatic breast cancer (MBC) not previously treated with a taxane. SCIE 2.2 ONCOLOGY
Bae, Ki Beom
(Bae, KB)


[JCR상위 2.2] Clinical efficacy and safety of early adjuvant chemotherapy for stage III colon cancer: Short-term outcomes of a multicenter, randomized, open-label, phase 3 trial. SCIE 2.2 ONCOLOGY
Baek, Seong Kyu
(Baek, SK)


[JCR상위 2.2] Clinical efficacy and safety of early adjuvant chemotherapy for stage III colon cancer: Short-term outcomes of a multicenter, randomized, open-label, phase 3 trial. SCIE 2.2 ONCOLOGY
Beom, Seung-Hoon
(Beom, SH)
Yonsei Univ, Yonsei Canc Ctr, Dept Internal Med, Seoul, South Korea

[JCR상위 2.2] PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer SCIE 2.2 ONCOLOGY ykkang@amc.seoul.kr;
Bondarenko, Igor
(Bondarenko, I)
U-5156-2017
Bondarenko, Igor
0000-0002-7071-2471
Bondarenko, Igor
[JCR상위 2.2] Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor plus (HR+), HER2-metastatic breast cancer (MBC) not previously treated with a taxane. SCIE 2.2 ONCOLOGY
Chic, Nuria
(Chic, N)


[JCR상위 2.2] Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor plus (HR+), HER2-metastatic breast cancer (MBC) not previously treated with a taxane. SCIE 2.2 ONCOLOGY
Cho, Sang Hee
(Cho, SH)
Chonnam Natl Univ, Hwasun Hosp, Dept Internal Med, Med Sch, Jeonnam, South Korea

[JCR상위 2.2] PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer SCIE 2.2 ONCOLOGY ykkang@amc.seoul.kr;
Choi, Jin-Hyuk
(Choi, JH)
Ajou Univ, Dept Hematol Oncol, Sch Med, Suwon, South Korea S-1679-2017
Choi, Jin

[JCR상위 2.2] PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer SCIE 2.2 ONCOLOGY ykkang@amc.seoul.kr;
Chung, Chi-Feng
(Chung, CF)


[JCR상위 2.2] Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor plus (HR+), HER2-metastatic breast cancer (MBC) not previously treated with a taxane. SCIE 2.2 ONCOLOGY
Gomez, Patricia
(Gomez, P)
JFB-3275-2023
GÓMEZ, PATRICIA

[JCR상위 2.2] Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor plus (HR+), HER2-metastatic breast cancer (MBC) not previously treated with a taxane. SCIE 2.2 ONCOLOGY
페이지 이동: